Immunotherapy

1. Monoclonal antibody-based therapeutics for leukemia.

Author
Li Y; Zhu Z; Li Y; Zhu Z;
Institution
Experimental Therapeutics, ImClone Systems, 180 Varick Street, New York, NY 10014, USA. yiwen.li@imclone.com
Journal
Expert Opin Biol Ther. 2007 Mar;7(3):319-30.
Abstract URL
Click here to view abstract

2. Immunomodulatory drugs in chronic lymphocytic leukemia: A new treatment paradigm.

Author
Molica S; Molica S;
Institution
Department Hematology/Oncology, Medical Oncology Unit. Catanzaro. Italy.
Journal
Leuk Lymphoma. 2007 May;48(5):866-9.
Abstract URL
Click here to view abstract

3. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.

Author
Wierda, William; O'Brien, Susan; Wen, Sijin; Faderl, Stefan; Garcia-Manero, Guillermo; Thomas, Deborah; Do, Kim-Anh; Cortes, Jorge; Koller, Charles; Beran, Miloslav; Ferrajoli, Alessandra; Giles, Francis; Lerner, Susan; Albitar, Maher; Kantarjian, Hagop; Keating, Michael;
Institution
Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA. wwierda@mdanderson.org
Journal
J Clin Oncol 2005 Jun 20;23(18):4070-8. Epub 2005 Mar 14.
Abstract URL
Click here to view abstract

4. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

Author
Byrd, John C; Rai, Kanti; Peterson, Bercedis L; Appelbaum, Frederick R; Morrison, Vicki A; Kolitz, Jonathan E; Shepherd, Lois; Hines, John D; Schiffer, Charles A; Larson, Richard A;
Institution
Division of Hematology-Oncology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA. byrd3@medctr.osu.edu
Journal
Blood 2005 Jan 1;105(1):49-53. Epub 2004 May 11.
Abstract URL
Click here to view abstract